[1]
Robak, P.; Dróżdż, I.; Jarych, D.; Mikulski, D.; Węgłowska, E.; Siemieniuk-Ryś, M.; Misiewicz, M.; Stawiski, K.; Fendler, W.; Szemraj, J.; Smolewski, P.; Robak, T. The value of serum MicroRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients. Cancers (Basel), 2020, 12(9), 2569.
[http://dx.doi.org/10.3390/cancers12092569] [PMID: 32916955]
[http://dx.doi.org/10.3390/cancers12092569] [PMID: 32916955]
[2]
Robak, T.; Kaźmierczak, M.; Jarque, I.; Musteata, V.; Treliński, J.; Cooper, N.; Kiessling, P.; Massow, U.; Woltering, F.; Snipes, R.; Ke, J.; Langdon, G.; Bussel, J.B.; Jolles, S. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv., 2020, 4(17), 4136-4146.
[http://dx.doi.org/10.1182/bloodadvances.2020002003] [PMID: 32886753]
[http://dx.doi.org/10.1182/bloodadvances.2020002003] [PMID: 32886753]
[3]
Robak, P.; Węgłowska, E.; Dróżdż, I.; Mikulski, D.; Jarych, D.; Ferlińska, M.; Wawrzyniak, E.; Misiewicz, M.; Smolewski, P.; Fendler, W.; Szemraj, J.; Robak, T. Cytokine and chemokine profile in patients with multiple myeloma treated with bortezomib. Mediat Inflamm., 2020, 20201835836
[http://dx.doi.org/10.1155/2020/1835836 ] [PMID: 32587468]
[http://dx.doi.org/10.1155/2020/1835836 ] [PMID: 32587468]
[4]
Gdynia, G.; Robak, T.; Kopitz, J.; Heller, A.; Grekova, S.; Duglova, K.; Laukemper, G.; Heinzel-Gutenbrunner, M.; Gutenbrunner, C.; Roth, W.; Ho, A.D.; Schirmacher, P.; Shmitt, M.; Dreger, P.; Sellner, L. Distinct activities of glycolytic enzymes identify chronic lymphocytic leukemia patients with a more aggressive course and resistance to chemo-immunotherapy. E Biol. Med., 2018, 32, 125-133.
[http://dx.doi.org/10.1016/j.ebiom.2018.05.030] [PMID: 29884457]
[http://dx.doi.org/10.1016/j.ebiom.2018.05.030] [PMID: 29884457]
[5]
Robak, T.; Huang, H.; Jin, J.; Zhu, J.; Liu, T.; Samoilova, O.; Pylypenko, H.; Verhoef, G.; Siritanaratkul, N.; Osmanov, E.; Alexeeva, J.; Pereira, J.; Drach, J.; Mayer, J.; Hong, X.; Okamoto, R.; Pei, L.; Rooney, B.; van de Velde, H.; Cavalli, F. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N. Engl. J. Med., 2015, 372(10), 944-953.
[http://dx.doi.org/10.1056/nejmoa1412096] [PMID: 25738670]
[http://dx.doi.org/10.1056/nejmoa1412096] [PMID: 25738670]
[6]
Robak, T.; Jamroziak, K.; Gora-Tybor, J.; Stella-Holowiecka, B.; Konopka, L.; Ceglarek, B.; Warzocha, K.; Seferynska, I.; Piszcz, J.; Calbecka, M.; Kostyra, A.; Dwilewicz-Trojaczek, J.; Dmoszyñska, A.; Zawilska, K.; Hellmann, A.; Zdunczyk, A.; Potoczek, S.; Piotrowska, M.; Lewandowski, K.; Blonski, J.Z. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J. Clin. Oncol., 2010, 28(11), 1863-1869.
[http://dx.doi.org/10.1200/jco.2009.25.9630] [PMID: 20212251]
[http://dx.doi.org/10.1200/jco.2009.25.9630] [PMID: 20212251]
[7]
Robak, T.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Loscertales, J.; Catalano, J.; Afanasiev, B.V.; Larratt, L.; Geisler, C.H.; Montillo, M.; Zyuzgin, I.; Ganly, P.S.; Dartigeas, C.; Rosta, A.; Maurer, J.; Mendila, M.; Saville, M.W.; Valente, N.; Wenger, M.K.; Moiseev, S.I. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol., 2010, 28(10), 1756-1765.
[http://dx.doi.org/10.1200/jco.2009.26.4556] [PMID: 20194844]
[http://dx.doi.org/10.1200/jco.2009.26.4556] [PMID: 20194844]
[8]
Warzocha, K.; Fabianowska-Majewska, K.; Bloński, J.; Krykowski, E.; Robak, T. Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia. Eur. J. Cancer, 1997, 33(1), 170-173.
[http://dx.doi.org/10.1016/s0959-8049(96)00347-4] [PMID: 9071923]
[http://dx.doi.org/10.1016/s0959-8049(96)00347-4] [PMID: 9071923]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
72
3